TY - JOUR
T1 - Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis
AU - Khanna, Surabhi Agarwal
AU - Nance, John W.
AU - Suliman, Sally A.
N1 - Funding Information:
The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for development of this article. Writing support was provided by Elizabeth Ng and Wendy Morris of Fleishman-Hillard, London, UK, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals, Inc. Boehringer Ingelheim was given the opportunity to review the article for medical and scientific accuracy as well as intellectual property considerations. The authors wish to thank Dr. Nishant Gupta for reviewing their manuscript.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/5
Y1 - 2022/5
N2 - PURPOSE OF REVIEW: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc). We explore the importance of early detection, monitoring, and management of SSc-ILD.RECENT FINDINGS: All patients with SSc are at risk of ILD and should be screened for ILD at diagnosis using a high-resolution computed tomography (HRCT) scan. Some patients with SSc-ILD develop a progressive phenotype characterized by worsening fibrosis on HRCT, decline in lung function, and early mortality. To evaluate progression and inform treatment decisions, regular monitoring is important and should include pulmonary function testing, evaluation of symptoms and quality of life, and, where indicated, repeat HRCT. Multidisciplinary discussion enables comprehensive evaluation of the available information and its implications for management. The first-line treatment for SSc-ILD is usually immunosuppression. The antifibrotic drug nintedanib has been approved for slowing lung function decline in patients with SSc-ILD. Optimal management of patients with SSc-ILD requires a multidisciplinary and patient-centered approach.
AB - PURPOSE OF REVIEW: Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis (SSc). We explore the importance of early detection, monitoring, and management of SSc-ILD.RECENT FINDINGS: All patients with SSc are at risk of ILD and should be screened for ILD at diagnosis using a high-resolution computed tomography (HRCT) scan. Some patients with SSc-ILD develop a progressive phenotype characterized by worsening fibrosis on HRCT, decline in lung function, and early mortality. To evaluate progression and inform treatment decisions, regular monitoring is important and should include pulmonary function testing, evaluation of symptoms and quality of life, and, where indicated, repeat HRCT. Multidisciplinary discussion enables comprehensive evaluation of the available information and its implications for management. The first-line treatment for SSc-ILD is usually immunosuppression. The antifibrotic drug nintedanib has been approved for slowing lung function decline in patients with SSc-ILD. Optimal management of patients with SSc-ILD requires a multidisciplinary and patient-centered approach.
KW - Autoimmune diseases
KW - Connective tissue disease
KW - Pulmonary fibrosis
KW - Scleroderma
KW - Lung Diseases, Interstitial/diagnosis
KW - Humans
KW - Lung
KW - Fibrosis
KW - Scleroderma, Systemic
KW - Quality of Life
KW - Respiratory Function Tests
UR - http://www.scopus.com/inward/record.url?scp=85129206583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129206583&partnerID=8YFLogxK
U2 - 10.1007/s11926-022-01067-5
DO - 10.1007/s11926-022-01067-5
M3 - Review article
C2 - 35499699
AN - SCOPUS:85129206583
SN - 1523-3774
VL - 24
SP - 166
EP - 173
JO - Current Rheumatology Reports
JF - Current Rheumatology Reports
IS - 5
ER -